The 4-year survival of AML with defective MDM2 inhibitor-induced TP53-mediated apoptosis despite WT TP53 was dismal, at 19% when NPM1 was comutated and 6% when NPM1 was WT. Here, TP53 is linked to acute myeloid leukemia.